AME Company for Medical Supplies (9527) fair value: what the stock is really worth
We calculate from audited financials what AME Company for Medical Supplies is really worth. The fair value tells you whether the price is too high or too low, the quality score (0 to 100) how solid the business behind it is. 26 models, 37 quality factors, updated daily.
Watch AME Company for Medical Supplies for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for free
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 13, 2026.
How to read this chart
56‑month range 30.84 SAR – 142.14 SAR · fair‑value band 30.41 SAR – 112.50 SAR · the 68.35 SAR price screens above the 59.80 SAR fair value. Dashed = 300-day average. As of Sep 13, 2026.
Alf Meem Yaa for Medical Supplies and Equipment Company engages in the wholesale and retail trade of medical supplies in the Kingdom of Saudi Arabia.
Show more
Alf Meem Yaa for Medical Supplies and Equipment Company engages in the wholesale and retail trade of medical supplies in the Kingdom of Saudi Arabia. It offers Teoxane, a range of injectable hyaluronic acid-based dermal fillers to treat wrinkles; Deka medical laser systems and therapies; Magellan, an autologous concentration system that delivers concentrated platelets and cells; and Euromi medical, dermatological, and aesthetic surgery equipment. The company also provides Nabota, a botulinum product; GMV medical devices; Novavision electronic equipment and dermo-cosmetic products; Mint, an absorbable polydioxanone barbed suture for soft tissue approximation; and MesoJet aesthetic treatment devices. In addition, it engages in the distribution of perfumes, cosmetics, orthotic devices, decorative soaps, incenses, veterinary medicines, and medical equipment. The company was founded in 2005 and is based in Jeddah, the Kingdom of Saudi Arabia.
Stock analysis
AME Company for Medical Supplies (9527) currently trades at 68.35 SAR, while our model-based Fair Value estimate is 59.80 SAR, implying the stock looks roughly 14.3% overvalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of 144.13 SAR per share, and 12 of the 15 models we run sit above the 68.35 SAR price.
Bear case: the Asset-Based group reads lowest at 17.15 SAR, and 3 of the 15 models stay below the price. Evidence for this calculation is high.
Scenario range: 30.41 SAR (bear) to 112.50 SAR (bull), the price of 68.35 SAR sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 54/100 (solid quality), in the Healthcare sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
AME Company for Medical Supplies reported revenue of 305M SAR in FY2025 versus 151M SAR in FY2021, a compound +19.1%/yr. Reported net income was 35.0M SAR in FY2025, compounding +13.3%/yr from FY2021.
Key figures
Market cap 479M SAR (≈ $127M) · P/E ratio 13.7 · P/S ratio 1.57 · EPS (TTM) 5.00 SAR · Dividend yield 2.9% · Net margin 11.5% · Return on equity 20.7% · Return on assets (EBIT) 18.9%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 50 out of 100 (low confidence).
What moves the price
The share trades about 50% below its 52-week high and 1% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at −13%, 9527 screens richer than that median.
Fair Value models
Bear 30.41 SARFair Value 59.80 SARBull 112.50 SAR
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 8 months old). Earnings retained since then (2.11 SAR per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.62/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+22.8%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+16.4%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+20.2%
Revenue growth 6 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+22.6%
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
+13.6%
Earnings growth per share plus dividend.
Earnings per share, growth per year+10.7%
Dividend (yield on the price)2.9%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.19% → 14%
Compare AME Company for Medical Supplies with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Distribution · 79 stocks
Beats the industry median on 10/12 measures
Overall it ranks above its industry peers.
Valuation
Quality Score54 · Above median
Fair Value upside+23% · Above median
Profitability
Return on equity (TTM)21% · Top 25%
Return on assets10% · Top 25%
Net margin (TTM)11% · Top 25%
Operating margin (TTM)7% · Above median
Growth and dividend
Revenue growth25% · Top 25%
Dividend yield (TTM)2.9% · Below median
Valuation Multiplesvs Medical Distribution median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "AME Company for Medical Supplies Fair Value". https://www.fairvalue-calculator.com/stock/9527
Frequently asked questions
Is AME Company for Medical Supplies (9527) overvalued or undervalued?
As of Sep 13, 2026, our model estimates a fair value of 59.80 SAR versus a price of 68.35 SAR, about −13% upside (overvalued).
What is the fair value of 9527?
Our model-based fair value for AME Company for Medical Supplies is 59.80 SAR (as of Sep 13, 2026), built from audited fundamentals. The current price: 68.35 SAR.
What is the quality score of 9527?
AME Company for Medical Supplies has a Quality Score of 54/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for AME Company for Medical Supplies (9527)?
Our model-based price target is the fair value of 59.80 SAR (as of Sep 13, 2026) from 15 valuation models. Cautious scenario 30.41 SAR, optimistic scenario 112.50 SAR. It is a calculation from audited fundamentals, not an analyst target.
What is the AME Company for Medical Supplies stock forecast for 2026?
Our models put fair value at 59.80 SAR, about −13% upside versus a price of 68.35 SAR (overvalued). Cautious scenario 30.41 SAR, optimistic scenario 112.50 SAR. The calculation is refreshed regularly with new filings.
What is the revenue of AME Company for Medical Supplies (9527)?
AME Company for Medical Supplies reported trailing-twelve-month revenue of about 305M SAR (latest available figure, as of Sep 13, 2026).
Does AME Company for Medical Supplies pay a dividend?
AME Company for Medical Supplies currently shows a dividend yield of about 2.93% relative to its recent price (as of Sep 13, 2026).
What is the intrinsic value of AME Company for Medical Supplies (9527)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For AME Company for Medical Supplies it is 59.80 SAR per share (as of Sep 13, 2026), against a price of 68.35 SAR. It is the blended result of 15 valuation models (cash flow, earnings, asset, dividend).
Is AME Company for Medical Supplies stock overvalued or undervalued in 2026?
As of Sep 13, 2026, 9527 trades above its calculated fair value: price 68.35 SAR, fair value 59.80 SAR, a gap of about −13% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 9527?
No. The price is what the market pays today (68.35 SAR); the fair value is what the company's own numbers justify (59.80 SAR). For AME Company for Medical Supplies the two are 8.55 SAR per share apart. That gap is exactly why we show both numbers side by side.
How much is AME Company for Medical Supplies worth?
The market values AME Company for Medical Supplies at about 479M SAR (market capitalisation, as of Sep 13, 2026). Per share that is 68.35 SAR; our models calculate a fair value of 59.80 SAR per share.
What do the bullish and bearish scenarios say about 9527?
Our models span a range for AME Company for Medical Supplies: cautious scenario 30.41 SAR, base 59.80 SAR, optimistic 112.50 SAR per share (as of Sep 13, 2026, price 68.35 SAR). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 9527?
AME Company for Medical Supplies trades at a price-to-earnings ratio of 13.7 (as of Sep 13, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 59.80 SAR is built from several models across several years. Other multiples: P/B 0.7, P/S 0.4, EV/EBITDA 2.8.
How solid is the balance sheet of AME Company for Medical Supplies (9527)?
Balance-sheet figures for AME Company for Medical Supplies (as of Sep 13, 2026): return on equity 20.7%. They feed the Quality Score of 54/100, which measures business quality independently of the share price.
How far is 9527 from its 52-week high?
AME Company for Medical Supplies trades at 68.35 SAR, about 50% below its 52-week high of 136.22 SAR and 1% above the low of 68.00 SAR (as of Sep 13, 2026). Distance from the high says nothing about value: that is what the fair value of 59.80 SAR is for.
Which stocks are comparable to AME Company for Medical Supplies?
From the same area (Healthcare) we also value McKesson Corporation, Cencora, Inc, Cardinal Health, Inc, Henry Schein, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is AME Company for Medical Supplies stock attractive at the current price?
The data as of Sep 13, 2026: price 68.35 SAR, calculated fair value 59.80 SAR (−13%), Quality Score 54/100, from 15 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 9527 calculated?
We run AME Company for Medical Supplies through 15 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 59.80 SAR, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 15.8 % above its aggregate fair value. AME Company for Medical Supplies itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What should I pay attention to with AME Company for Medical Supplies right now?
The model range is unusually wide (30.41 SAR to 112.50 SAR). The outcome hinges heavily on assumptions, so read the point estimate with caution. Solid but not exceptional quality (54/100) and above fair value, neither a clear bargain nor a standout compounder.
Key figures of AME Company for Medical Supplies
How large is the market capitalisation of AME Company for Medical Supplies (9527)?
The market capitalisation of AME Company for Medical Supplies is 479M SAR (≈ $127M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of AME Company for Medical Supplies (9527)?
The price-to-sales ratio of AME Company for Medical Supplies is 1.57 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of AME Company for Medical Supplies (9527)?
Earnings per share at AME Company for Medical Supplies are 5.00 SAR (price ÷ EPS = P/E 13.7). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of AME Company for Medical Supplies (9527)?
The dividend yield of AME Company for Medical Supplies is 2.9% (payout 40.0%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of AME Company for Medical Supplies (9527)?
The net margin of AME Company for Medical Supplies is 11.5% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of AME Company for Medical Supplies (9527)?
The return on equity (ROE) of AME Company for Medical Supplies is 20.7% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of AME Company for Medical Supplies (9527)?
On an EBIT basis the return on assets of AME Company for Medical Supplies is 18.9% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of AME Company for Medical Supplies (9527)?
The operating margin of AME Company for Medical Supplies is 7.5% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at AME Company for Medical Supplies (9527)?
Revenue at AME Company for Medical Supplies is growing +24.9% versus a year earlier (3y avg +16.4%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at AME Company for Medical Supplies (9527)?
Earnings per share at AME Company for Medical Supplies are growing −62.2% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does AME Company for Medical Supplies (9527) generate?
The free cash flow of AME Company for Medical Supplies is −27.2M SAR (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does AME Company for Medical Supplies (9527) carry?
The net debt of AME Company for Medical Supplies is 17.3M SAR (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch AME Company for Medical Supplies in the live analysis
One click puts AME Company for Medical Supplies on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
